Rezdiffra
Payments companies reported to CMS as associated with Rezdiffra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rezdiffra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rezdiffra
These are the largest totals companies reported as associated with Rezdiffra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sushama Scalera | Salem, MA | Emergency Medicine | $613,288.00 |
| Cynthia Guy | Durham, NC | Anatomic Pathology & Clinical Pathology | $378,870.56 |
| Zahid Vahora | Washington, DC | Transplant Hepatology | $359,043.69 |
| Santiago Munoz | Toms River, NJ | Transplant Hepatology | $356,699.01 |
| Naim Alkhouri | Westlake, OH | Gastroenterology (Internal Medicine) | $309,024.94 |
| Anthony Martinez | Buffalo, NY | Internal Medicine | $231,277.52 |
| Nadege Gunn | Waco, TX | Gastroenterology (Internal Medicine) | $215,838.68 |
| Pierre Gholam | Cleveland, OH | Gastroenterology (Internal Medicine) | $212,595.69 |
| Julio Gutierrez | Los Angeles, CA | Transplant Hepatology | $201,312.45 |
| Sonja Olsen | West Palm Beach, FL | Gastroenterology (Internal Medicine) | $193,109.25 |
Prescribed Rezdiffra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.